Results 171 to 180 of about 173,141 (216)
Some of the next articles are maybe not open access.
Immunosuppression and HBV Reactivation
Seminars in Liver Disease, 2013Hepatitis B virus (HBV) reactivation following immunosuppression is defined by an abrupt rise in HBV replication followed by laboratory signs of hepatocellular injury in a "silent" hepatitis B surface antigen (HBsAg) carrier. Reactivation can also occur, albeit at a lower rate, in patients with occult HBV infection.
Daniel, Shouval, Oren, Shibolet
openaire +2 more sources
Current Gene Therapy, 2003
The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body.
Ruian, Xu +5 more
openaire +2 more sources
The hepatitis B virus (HBV) infection is a public health problem worldwide, particularly in East Asia. The current therapy of HBV infection is mostly based on chemical agents and cytokines that have been shown to provide limited efficacy and are also toxic to the human body.
Ruian, Xu +5 more
openaire +2 more sources
Journal of Hepatology, 2006
Hepatitis B may cause liver damage ranging from mild chronic hepatitis to severe active hepatitis, cirrhosis and hepatocellular carcinoma. HIV and HBV co-infection is more likely to lead to lower rates of HBeAg seroconversion, and higher HBV DNA concentrations. Immune restitution may lead to more severe hepatitis.
openaire +2 more sources
Hepatitis B may cause liver damage ranging from mild chronic hepatitis to severe active hepatitis, cirrhosis and hepatocellular carcinoma. HIV and HBV co-infection is more likely to lead to lower rates of HBeAg seroconversion, and higher HBV DNA concentrations. Immune restitution may lead to more severe hepatitis.
openaire +2 more sources
Clinics and Research in Hepatology and Gastroenterology, 2014
Several recent papers support the view that Na-taurocholate cotransporting polypeptide (NTCP), the sinusoidal bile acid transporter of hepatocytes, is a cell surface receptor enabling entry into these cells of the hepatitis B virus (HBV). This major advance in the understanding of the HBV life cycle paves the way to new therapeutic strategies aimed at ...
openaire +2 more sources
Several recent papers support the view that Na-taurocholate cotransporting polypeptide (NTCP), the sinusoidal bile acid transporter of hepatocytes, is a cell surface receptor enabling entry into these cells of the hepatitis B virus (HBV). This major advance in the understanding of the HBV life cycle paves the way to new therapeutic strategies aimed at ...
openaire +2 more sources
1999
The natural history of infection in patients with active HBV viral replication (HBsAg, HBeAg and HBV DNA positive) tends to be progressive, with development of long-term complications such as portal hypertension and hepatic decompensation. As well, the risk of developing hepatocellular carcinoma (HCC) is increased 10 to 390-fold in patients with ...
M G, Pessoa, T L, Wright
openaire +2 more sources
The natural history of infection in patients with active HBV viral replication (HBsAg, HBeAg and HBV DNA positive) tends to be progressive, with development of long-term complications such as portal hypertension and hepatic decompensation. As well, the risk of developing hepatocellular carcinoma (HCC) is increased 10 to 390-fold in patients with ...
M G, Pessoa, T L, Wright
openaire +2 more sources